Concord Biotech Limited announced the appointment of Mr. Raviraj Karia as the new Chief Financial Officer (CFO) of the company. This key managerial personnel appointment was approved by the Board of Directors, following recommendations from the Nomination and Remuneration Committee and the Audit Committee. The appointment is effective from December 18, 2025. Mr. Karia is a Chartered Accountant with over 23 years of extensive experience in finance and leadership roles across various sectors, including pharmaceuticals, healthcare, and private equity. His expertise spans corporate governance, strategic finance, and business partnering. He has previously held significant positions at companies such as Intas Pharmaceuticals and Gati, where he managed large financing programs and played a key role in strategic financial initiatives. The Board meeting where this appointment was approved commenced at 12:10 PM and concluded at 12:50 PM on December 18, 2025. Mr. Karia is not related to any of the Directors of Concord Biotech Limited and holds no shares in the company.